Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: COVID-19 infections - Berono group/Tianjin University

Drug Profile

Research programme: COVID-19 infections - Berono group/Tianjin University

Latest Information Update: 28 Feb 2020

At a glance

  • Originator Beroni Group; Tianjin University
  • Class Antibodies; Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 09 Mar 2020 Beroni plans to conduct animal experiments followed by clinical trials in April 2020
  • 20 Feb 2020 Beroni group collaborates with Tianjin University to develop coronavirus therapeutic
  • 20 Feb 2020 Early research in COVID-2019-infections in China (Parenteral) before February 2020

Development Overview

Introduction

A coronavirus therapeutic is being jointly developed by Berono group and Tianjin University for the treatment of COVID-2019 infections caused by SARS-CoV-2 using nanobody-based technology. The therapeutic will be developed by leveraging computer-aided drug design to predict the complex structure of SARS-CoV-2 with various neutralizing antibodies. The nano body based technology will also be used to identify the crystal structure of nano-antibodies and antigens, as well as understand the structural binding between antigens. The development of binding nanobodies improves the detection rate as well as the accuracy of SARS-CoV-2 and also facilitates the treatment of COVID-19. Early research is underway in China.

Company Agreements

In February 2020, Beroni Group entered into a research and development agreement with Tianjin University in China to develop targeted treatment and quick detection technique for COVID-2019-infections. [1]

Key Development Milestones

In March 2020, Beroni group announced that the research of medical solution has advanced into the cytological experiments. Beroni plans to conduct animal experiments followed by clinical trials in April 2020 [2] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antibodies, Antivirals
  • Mechanism of Action Immunomodulators
  • WHO ATC code

    J05 (Antivirals for Systemic Use)

  • EPhMRA code

    J5 (Antivirals for Systemic Use)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research China Parenteral / unspecified Beroni Group, Tianjin University 20 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Tianjin University Originator China
Beroni Group Originator Australia
Beroni Group Owner Australia
Tianjin University Owner China

Future Events

Expected Date Event Type Description Updated
30 Apr 2020 Trial Update Beroni plans to conduct animal experiments followed by clinical trials in April 2020 [2] 13 Mar 2020

Development History

Event Date Update Type Comment
09 Mar 2020 Trial Update Beroni plans to conduct animal experiments followed by clinical trials in April 2020 [2] Updated 13 Mar 2020
20 Feb 2020 Licensing Status Beroni group collaborates with Tianjin University to develop coronavirus therapeutic [1] Updated 28 Feb 2020
20 Feb 2020 Phase Change Early research in COVID-2019-infections in China (Parenteral) before February 2020 [1] Updated 28 Feb 2020

References

  1. Beroni Group Collaborates with Tianjin University to Develop Novel Solution for Coronavirus (COVID-19).

    Media Release
  2. Beroni Group Advances Research and Development of Medical Solution for Coronavirus (COVID-19).

    Media Release
Back to top